{
    "code": "60000999",
    "url": "https:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=60000999",
    "time": "2019-06-07 03:39:59",
    "許可證字號": "衛部菌疫輸字第000999號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "有效日期": "109\/12\/24",
    "發證日期": "104\/12\/24",
    "許可證種類": "菌　疫",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA06000099908",
    "中文品名": "欣銳擇 注射劑",
    "英文品名": "CYRAMZA injection",
    "適應症": "1.胃癌\r\n(1) Ramucirumab併用paclitaxel適用於治療正接受或接受過fluoropyrimidine和platinum化學治療仍疾病惡化之晚期或轉移性胃腺癌(或胃食道接合處腺癌)。\r\n(2) Ramucirumab單一藥物適用於治療正接受或接受過fluoropyrimidine或platinum化學治療仍疾病惡化，且不適合接受含paclitaxel藥物治療之晚期或轉移性胃腺癌(或胃食道接合處腺癌)。\r\n2.非小細胞肺癌(NSCLC)\r\nRamucirumab併用docetaxel適用於治療正接受或接受過含platinum化學治療仍疾病惡化之局部晚期或轉移性非小細胞肺癌。\r\n3.大腸直腸癌\r\nRamucirumab併用FOLFIRI (irinotecan、葉酸及5-fluorouracil)適用於治療正接受或接受過bevacizumab、oxaliplatin及fluoropyrimidine治療仍疾病惡化之轉移性大腸直腸癌(mCRC)。",
    "劑型": "270注射劑",
    "包裝": "100毫克，500毫克玻璃小瓶裝 各100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": [
        ""
    ],
    "藥品類別": "06須由醫師處方使用",
    "主成分略述": "Ramucirumab",
    "主製造廠": {
        "申請商名稱": "1411301100  台灣禮來股份有限公司",
        "申請商地址": "台北市復興北路３６５號１１樓",
        "主製造廠": "",
        "製造廠名稱": "FUS0073100  ELI LILLY AND COMPANY"
    },
    "CCC號列": "",
    "藥理治療分類": "",
    "次製造廠": [
        {
            "製造廠名稱": "FIE0009000  Eli Lilly Kinsale Limited",
            "製造廠廠址": "DUNDERROW, KINSALE COUNTRY CORK.",
            "製造廠公司地址": "",
            "製造廠國別": "IRELAND",
            "製程": "原料藥製造廠"
        },
        {
            "製造廠名稱": "FUS0665000  IMCLONE SYSTEM CORPORATION",
            "製造廠廠址": "IMCLONE DRIVE, BRANCHBURG, NJ 08876 USA",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED STATES",
            "製程": "原料藥製造廠"
        }
    ],
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013005500",
            "成分名稱": "Ramucirumab",
            "含量描述": "",
            "含量": "10.0000000000",
            "單位": "MG\/ML"
        }
    ],
    "仿單外盒": [
        {
            "title": "CYRAMZA中文仿單 201712-108-03-26(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60000999&Seq=006&Type=9"
        },
        {
            "title": "020009990002-英文-106-12-12.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60000999&Seq=005&Type=9"
        },
        {
            "title": "020009990001-中文-106-12-12.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60000999&Seq=004&Type=9"
        },
        {
            "title": "Cyramza 100mg-carton-108-03-26(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60000999&Seq=007&Type=8"
        },
        {
            "title": "Cyramza 500mg-carton-108-03-26(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60000999&Seq=006&Type=8"
        },
        {
            "title": "020009990005 100 carton-105-01-19.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60000999&Seq=003&Type=8"
        }
    ]
}